Syndecan-4 Is An Independent Predictor Of All-Cause As Well As Cardiovascular Mortality In Hemodialysis Patients

BackgroundLeft ventricular hypertrophy is associated withincreased mortality in hemodialysis (HD) patients. Syndecan-4 plays a role in many processes that are involved in the heart fibrosis and hypertrophy. We designed this study to prospectively determine whether syndecan-4 was predictive of mortality in a group of HD patients.MethodsIn total, 191 HD patients were included. Clinical, biochemical and echocardiographic parameters were recorded. HD patients were followed-up for 23.18 +/- 4.02 months.ResultsSyndecan-4 levels correlated strongly with geometrical echocardiographic parameters and ejection fraction. Relations with pressure-related parameters were weak and only marginally significant. Using the receiver operating characteristics the optimal cut-off points in predicting all-cause as well as cardiovascular (CV) mortality were evaluated and patients were divided into low and high syndecan-4 groups. A Kaplan-Meier analysis showed that the cumulative incidences of all-cause as well as CV mortality were higher in high serum syndecan-4 group compared with those with low serum syndecan-4 (p<0.001 in both cases). A multivariate Cox proportional hazards regression analysis revealed syndecan-4 concentration to be an independent and significant predictor of all-cause (hazard ratio, 2.99; confidence interval, 2.34 to 3.113; p<0.001) as well as CV mortality (hazard ratio, 2.81; confidence interval, 2.28to3.02; p<0.001).ConclusionsSerum syndecan-4 concentration reflects predominantly geometrical echocardiographic parameters. In HD patients serum syndecan-4 concentration is independently associated with all-cause as well as CV mortality.